1. 158 198 197 200 222 38 77 130 106 151 212 183 205 235 209 226 255 150 191 Theme Colours 242 217 HSV Oncolytic Immunotherapy BioTrinity 2016 Lynne Braidwood VP Business Development Virttu Biologics lynne.braidwood@virttu.com 44 (0)141 445 1716

2. 158 198 197 200 222 38 77 130 106 151 212 183 205 235 209 226 255 150 191 Theme Colours 242 217  VIRTTU is a privately held biotech which has pioneered the development of oncolytic viruses for treating cancers.  Our lead product, SEPREHVIR has been administered, by various routes into nearly 100 patients.  Our in house expertise has lead to the development to techniques to rapidly engineer further therapeutic modalities into the SEPREHVIR backbone, generating a promising pipeline of new generation products.  We have over 15 years of research and development activity both in house and with leading researchers in the field, leading to many firsts and 68 peer reviewed published papers

3. 158 198 197 200 222 38 77 130 106 151 212 183 205 235 209 226 255 150 191 Theme Colours 242 217 Mode of Action - Cancer Immunotherapy via Tumor Selective Oncolysis  Highly selective tumor cell replication kills cancer cells (oncolysis)  Stimulates the innate and adaptive immune responses within tumors leading to anti-tumor immunity  Potential for a lifetime of protection via long-lasting durable vaccination SEPREHVIR Tumor Immunogenic Cell Death HMGB1, HSP70, HSP90 IFNγ Immune Cell Recruitment Cytokine/ chemokine NK, Mø, Tcells Anti-Tumor Immune Response Cytotoxic T cells Cytokine/chemokine 2

4. 158 198 197 200 222 38 77 130 106 151 212 183 205 235 209 226 255 150 191 Theme Colours 242 217 Oncolytics viruses – the beginnings Dock (1904) reported that leukaemia patients blood counts improved after natural infection. In 1910 DePace reported how a woman with a large cervical cancer had a complete remission after receiving a live attenuated rabies vaccine after being bitten by a dog.

5. 158 198 197 200 222 38 77 130 106 151 212 183 205 235 209 226 255 150 191 Theme Colours 242 217 Last year, the oncolytic virus field took a giant leap forward with the first oncolytic virus approval by the FDA as a cancer treatment. Looking forward, VIRTTU is building on its strong foundation of research and development to make the best –in –class oncolytic that: _____________________________________________________________________ Oncolytic Immunotherapy comes of age 4  Have enhanced oncolysis  Potently stimulate an anti tumour effect  Can be delivered systemically  Can be used in a broad spectrum of cancers  Can be used in combination with current or new standard of care  Include transgenes to deliver addition effect  Optimized manufacturing  Optimized storage

6. 158 198 197 200 222 38 77 130 106 151 212 183 205 235 209 226 255 150 191 Theme Colours 242 217 NEW GENERATION oHSV  Develop and select multi-function, novel products based on new generation oHSV with enhanced oncolysis and immunotherapy SEPREHVIR  Efficiently complete clinical study to confirm the mechanism of action and potential safety and efficacy of intravenous SEPREHVIR VIRTTU Strategy _____________________________________________________________________ 5

7. 158 198 197 200 222 38 77 130 106 151 212 183 205 235 209 226 255 150 191 Theme Colours 242 217 Large DNA Genome Easy to Manipulate Proprietary Backbones With Improved Potency Proprietary Engineering Enables Rapid Production Proprietary Multi-Gene Inserts Proprietary Manufacturing Process VIRTTU has a proprietary platform technology (SEPREHVEC) for generation of new generation vectors 6

8. 158 198 197 200 222 38 77 130 106 151 212 183 205 235 209 226 255 150 191 Theme Colours 242 217 SEPREHVEC: Rapid Production of Novel oHSV Site-specific recombination within RL1 loci  Streamlined patented method  Avoids complex multi-step in vivo procedures  Highly efficient - with colour selection  Rapid isolation of recombinant viruses in days  0.1 – 6kbp inserts/ separate ORFs  Synthetic gene constructs for recombinant design 7

9. 158 198 197 200 222 38 77 130 106 151 212 183 205 235 209 226 255 150 191 Theme Colours 242 217 Best-in-Class Optimized for Anti-Tumor Immunity Rational design of new generation oHSV:-  Proprietary backbone with enhanced oncolysis  Multi-mechanistic modes of action in a single agent  High therapeutic ratio- intratumoral expression reduces toxicity profiles  Multi-hit single therapy for ease of re-imbursement Adapted from Mellman et al (2011) Cancer immunotherapy comes of age. Nature 180; 480-489 8

10. 158 198 197 200 222 38 77 130 106 151 212 183 205 235 209 226 255 150 191 Theme Colours 242 217 1x10 6 pfu on days 0 and 3 1x10 6 pfu on days 0 and 3  SEPREHVIR variant with an oncolytic accelerator transgene (ING4) for enhanced potency  Enhanced therapeutic potential of HSV1716ING4 in a challenging model Growth Survival HSV1716ING4 vs HSV1716 P=0.0092 Transgene Insertion into SEPREHVIR Backbone Enhances Efficacy SEPREHVIR HSV1716ING4 No virus SEPREHVIR HSV1716ING4 No virus 9 Preclinical xenograft study in challenging SCC mouse model HSV1716ING4 vs Seprehvir P=0.0092

11. 158 198 197 200 222 38 77 130 106 151 212 183 205 235 209 226 255 150 191 Theme Colours 242 217 Milestones and Timelines: Best-in-Class Create proprietary backbone technology Generate multi-gene candidates using SEPREHVEC Characterization in vitro and in vivo Most potent candidates for pre-clinical development Manufacturing, Toxicology and Biodistribution cGMP manufacture for clinical study, Systemic CTA/IND filed 2.5 yrs Cost: 5 million GBP over 2.5 years 10

12. 158 198 197 200 222 38 77 130 106 151 212 183 205 235 209 226 255 150 191 Theme Colours 242 217 SEPREHVIR: Reprogrammed HSV  Targets and directly kills cancer cells  Stimulates long lasting tumor-specific immunity  Intravenous administration  Broad Spectrum  Safety established in 97 patients  Phase 2-ready  Can be used in combination with current and future standard of care treatments. _____________________________________________________________________ Targeted Oncolytic Immunotherapy 11

13. 158 198 197 200 222 38 77 130 106 151 212 183 205 235 209 226 255 150 191 Theme Colours 242 217 n=10 n=11n=12 n=11 Time post first dose of virus treatment (Day) Survival (%) Tumor Vol.( mm 3 ) SEPREHVIR/Ctrl AbPBS/Anti PD-1 PBS/Ctrl Ab SEPREHVIR/Anti PD-1 Combination of SEPREHVIR with Anti-PD-1 Significantly Improves Efficacy P<0.0001 P=0.004 P=0.019 P=0.0145 P=0.0044 12

14. 158 198 197 200 222 38 77 130 106 151 212 183 205 235 209 226 255 150 191 Theme Colours 242 217 Objectives  Confirm intravenous SEPREHVIR targets only cancer cells sparing healthy cells  Finalize the dose selection and dosing regimen  Demonstrate tumor targeting and safety  Reconfirm that SEPREHVIR stimulates an anti-tumor response Study  Intravenous SEPREHVIR in ~50 patients with biopsy accessible/resectable solid tumors  2 dose levels/3 regimen Systemic SEPREHVIR - Phase 1/2 Objectives & Studies 13

15. 158 198 197 200 222 38 77 130 106 151 212 183 205 235 209 226 255 150 191 Theme Colours 242 217 IV delivery of SEPREHVIR in multiple solid tumors 2 doses levels 3 regimen Biopsy/resection to confirm tumor targeting Confirm Immunological Efficacy Proven Safety and Successful Tumor Delivery for IV SEPREHVIR Milestones and timelines: Intravenous SEPREHVIR 2yrs Cost: 4 million GBP over 2 years 14

16. 158 198 197 200 222 38 77 130 106 151 212 183 205 235 209 226 255 150 191 Theme Colours 242 217 Why partner up with VIRTTU? Unique and promising immunotherapeutic approach to transforming the treatment of cancer, patient quality of life and cost of care Scientific leadership in HSV oncolytic immunotherapy Therapeutic validation via T-VEC approval Versatile platform facilitates improved backbones, multi-functional products & proprietary, rapid production of armed oHSV Targeted immunotherapy, intravenous oHSV Manufacturing process in place – opportunity to optimize Rapid path to clinic 15

17. 158 198 197 200 222 38 77 130 106 151 212 183 205 235 209 226 255 150 191 Theme Colours 242 217 HSV Oncolytic Immunotherapy BioTrinity 2016 Lynne Braidwood VP Business Development Virttu Biologics lynne.braidwood@virttu.com 44 (0)141 445 1716